Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity
- PMID: 33582005
- PMCID: PMC8611374
- DOI: 10.1016/j.pan.2021.02.003
Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity
Abstract
Background: /Objectives: Pancreatic adenocarcinoma (PDAC) metastatic to the leptomeninges is a rare and lethal event. Leptomeningeal disease (LMD) research is limited in PDAC, and insights into clinical descriptors, possible disease predictors, and treatment strategies is necessitated.
Methods: Memorial Sloan Kettering databases were queried with Institutional Review Board approval to identify patients with LMD and PDAC treated between January 2000 and June 2020. Medical record review was used to abstract clinical, genomic, pathologic, and radiographic data. Overall survival was calculated from date of PDAC diagnosis to date of death. Previously published literature on LMD from PDAC was reviewed.
Results: Four patients with LMD from PDAC were identified, two males and two females. Age at diagnosis ranged from 57 to 68 years. All four patients had predominant lung metastasis and a relatively low burden of intra-abdominal disease. Somatic testing indicated alterations typical of PDAC and no PDAC defining pathogenic germline mutations were identified. An extended clinical course prior to LMD diagnosis was observed in all patients, ranging from 16 to 148 months. Upon diagnosis of LMD, three patients elected for supportive care and one patient received a limited course of craniospinal radiation. The median survival following diagnosis of LMD was 1.6 months (range 0.5-2.8 months).
Conclusions: LMD from PDAC is a rare occurrence that may be more frequent in patients with lung metastasis and/or a more indolent clinical course. Following diagnosis of LMD, prognosis is poor, and survival is short. New treatment strategies for this manifestation of PDAC are needed.
Keywords: Cerebrospinal fluid; Genomics; Leptomeninges; Pancreatic adenocarcinoma.
Copyright © 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest EOR Research Funding to MSK: Genentech/Roche, Celgene/BMS, BioNTech, BioAtla, AstraZeneca, Arcus. EOR Consulting Role: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Sobi, Silenseed, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen (+spouse), Polaris (+spouse), Merck (+spouse), AstraZeneca (+spouse), Bayer (spouse), Genentech/Roche (spouse), Celgene/BMS (spouse), Eisai (spouse). No other authors have disclosures.
Figures



Similar articles
-
The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.J Surg Oncol. 2015 Jul;112(1):80-5. doi: 10.1002/jso.23943. Epub 2015 Jul 7. J Surg Oncol. 2015. PMID: 26153355 Free PMC article.
-
Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7. Clin Colorectal Cancer. 2018. PMID: 29496399 Free PMC article.
-
Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience.Neurology. 2019 May 21;92(21):e2483-e2491. doi: 10.1212/WNL.0000000000007529. Epub 2019 Apr 24. Neurology. 2019. PMID: 31019097 Free PMC article.
-
Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.World J Gastroenterol. 2017 Sep 21;23(35):6420-6428. doi: 10.3748/wjg.v23.i35.6420. World J Gastroenterol. 2017. PMID: 29085191 Free PMC article. Review.
-
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease.Semin Oncol. 2024 Jun-Aug;51(3-4):69-76. doi: 10.1053/j.seminoncol.2024.04.001. Epub 2024 May 3. Semin Oncol. 2024. PMID: 38879350 Review.
Cited by
-
A Rare Case of Brain Metastases in an Elderly Patient With Primary Pancreatic Cancer.Cureus. 2022 Aug 1;14(8):e27578. doi: 10.7759/cureus.27578. eCollection 2022 Aug. Cureus. 2022. PMID: 36059331 Free PMC article.
-
A Rare Case of Simultaneous Brain and Leptomeningeal Metastases in a Patient With Pancreatic Cancer.Cureus. 2025 Mar 2;17(3):e79923. doi: 10.7759/cureus.79923. eCollection 2025 Mar. Cureus. 2025. PMID: 40171334 Free PMC article.
-
A Unique Case of a Patient With Pancreatic Cancer Developing Leptomeningeal Metastases While on Gemcitabine and Nab-Paclitaxel.Cureus. 2024 Apr 12;16(4):e58139. doi: 10.7759/cureus.58139. eCollection 2024 Apr. Cureus. 2024. PMID: 38738113 Free PMC article.
-
Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma.BMJ Case Rep. 2022 Jun 8;15(6):e249837. doi: 10.1136/bcr-2022-249837. BMJ Case Rep. 2022. PMID: 35675963 Free PMC article.
-
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.Oncologist. 2025 Jan 17;30(1):oyae182. doi: 10.1093/oncolo/oyae182. Oncologist. 2025. PMID: 39014543 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. 2018; 68: 7–30. - PubMed
-
- Beauchesne P: Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010; 11: 871–879. - PubMed
-
- Park KS, Kim M, Park SH, Lee KW: Nervous system involvement by pancreatic cancer. J Neurooncol 2003; 63: 313–316. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources